Quadrant Capital Group LLC increased its holdings in Novo Nordisk A/S (NYSE:NVO) by 2.3% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 17,378 shares of the company’s stock after buying an additional 390 shares during the quarter. Quadrant Capital Group LLC’s holdings in Novo Nordisk A/S were worth $874,000 at the end of the most recent reporting period.
Other large investors have also bought and sold shares of the company. Clearbridge Investments LLC raised its position in Novo Nordisk A/S by 42.3% in the first quarter. Clearbridge Investments LLC now owns 1,160,942 shares of the company’s stock worth $60,729,000 after purchasing an additional 344,989 shares in the last quarter. Janus Henderson Group PLC grew its stake in Novo Nordisk A/S by 11.4% during the first quarter. Janus Henderson Group PLC now owns 247,811 shares of the company’s stock worth $12,963,000 after buying an additional 25,382 shares during the last quarter. Hartwell J M Limited Partnership grew its stake in Novo Nordisk A/S by 7.2% during the first quarter. Hartwell J M Limited Partnership now owns 10,400 shares of the company’s stock worth $544,000 after buying an additional 700 shares during the last quarter. GYL Financial Synergies LLC bought a new stake in Novo Nordisk A/S during the first quarter worth about $1,090,000. Finally, Traynor Capital Management Inc. grew its stake in Novo Nordisk A/S by 1.1% during the first quarter. Traynor Capital Management Inc. now owns 71,706 shares of the company’s stock worth $3,750,000 after buying an additional 810 shares during the last quarter. 7.12% of the stock is owned by hedge funds and other institutional investors.
Shares of NVO traded up $0.15 during mid-day trading on Friday, hitting $48.72. 1,285,362 shares of the company traded hands, compared to its average volume of 1,684,996. Novo Nordisk A/S has a one year low of $41.23 and a one year high of $52.83. The company has a debt-to-equity ratio of 0.07, a current ratio of 0.96 and a quick ratio of 0.66. The business has a 50-day simple moving average of $49.84. The stock has a market capitalization of $117.40 billion, a PE ratio of 19.33, a price-to-earnings-growth ratio of 2.20 and a beta of 0.60.
Several analysts have weighed in on the stock. Barclays raised shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $51.85 price objective on the stock in a research note on Tuesday, June 11th. UBS Group reaffirmed a “buy” rating and set a $355.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, June 19th. Pareto Securities cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th. Deutsche Bank cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $52.42 price objective on the stock. in a research note on Thursday, June 20th. Finally, Credit Suisse Group raised shares of Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a research note on Monday, April 29th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have issued a buy rating to the company. Novo Nordisk A/S presently has an average rating of “Hold” and an average price target of $111.58.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Featured Article: Consumer behavior in bull markets
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.